To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
a:2:{s:4:"text";s:0:"";s:4:"show";b:1;} The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
The new PrenaTest®express allows pregnant women at risk to receive the test results within one week
1. October 2013 / by Katja Albert / 2013
Constance, Germany – With the new PrenaTest®express, LifeCodexx is able to reduce the waiting times for expectant mothers at risk for the test results to a maximum of one week. The PrenaTest®express is the innovative extension of the PrenaTest®, Europe’s first non-invasive molecular genetic blood test to determine fetal trisomies 13, 18 and 21 in the mother’s blood.
Read more
LifeCodexx performs close to 6,000 PrenaTest® analyses in its first year
22. August 2013 / by Katja Albert / 2013
Constance, Germany – In the first twelve months since its market launch in August 2012, nearly 6,000 women have decided for PrenaTest®. It is Europe’s first non-invasive molecular genetic blood test for the determination of fetal trisomies 13, 18 and 21 from maternal blood. The vast majority of the women (approx. 98%) could be relieved by an inconspicuous test result.
Read more
Improved PrenaTest® provides early knowledge for high risk pregnancies
8. July 2013 / by Katja Albert / 2013
Constance, Germany – PrenaTest®, Europe’s first non-invasive molecular genetic blood test to determine fetal trisomies 13, 18 and 21 in the mother’s blood can now be performed for high risk pregnancies after the ninth week (W 9 + D 0).
Read more
PrenaTest® now detects fetal trisomies 21, 18 and 13
13. February 2013 / by Katja Albert / 2013
Constance, Germany – PrenaTest®, Europe’s first non-invasive molecular genetic blood test to detect fetal trisomy 21 from maternal blood, now also tests for the existence of trisomy 13 and 18 with a high degree of accuracy.
Read more